MAGENTIQ EYE LTD., a leading innovator in AI-powered gastroenterology decision-support software, announced the successful completion of its Series A funding round on July 30, 2025. The investment, led by aMoon, Israel's largest HealthTech dedicated investment fund, will support commercialization efforts in the USA and Europe while advancing the development of the company's AI capabilities.
FDA-Approved Technology Enhances Colonoscopy Outcomes
The company's flagship product, MAGENTIQ-COLO™, has received both FDA and CE approval for enhancing polyp detection and analysis capabilities during colonoscopies. The AI-powered software significantly improves adenoma detection rates and provides real-time insights to gastroenterologists. The CE-approved version includes additional features such as polyp-size category and type estimation, along with advanced AI-generated reports.
"MAGENTIQ's solution stands out as the most accurate in the market, with the broadest set of features, cost-effective scalability, and platform flexibility across GI and laparoscopic applications," said Roy Wiesner, partner at aMoon, who will join MAGENTIQ EYE's board of directors following the investment.
Expanding Clinical Pipeline
Beyond colonoscopy applications, MAGENTIQ EYE is conducting clinical trials for diagnostic tools targeting specialized diseases throughout the gastrointestinal tract. The company's development pipeline includes tools for detecting ulcerative colitis, early dysplasia in Barrett's esophagus, and gastric intestinal metaplasia. Additionally, the company is developing automated quality indicators for GI procedures.
Strong Commercial Traction Drives Investment
The funding round attracted participation from multiple international investors, including Norgine Ventures BV (Netherlands), Nina Capital (EU & USA), Namarel Ventures SL (Spain), Nova Capital (Italy), and private investors Sake Bosch and Roon Doornink (USA). This diverse investor base reflects the global interest in the company's technology.
"With aMoon's support, we will accelerate innovation and market access, meeting the growing demand reflected in our robust pipeline of trial and purchase requests across the U.S. and Europe," said Dror Zur, Ph.D., founder and CEO of MAGENTIQ EYE.
The company reports dozens of procedures are performed daily with MAGENTIQ-COLO™ assistance, demonstrating real-world adoption of the technology. Founded in 2014, MAGENTIQ EYE has gained worldwide recognition from the gastroenterology community for its AI-aided colonoscopy solution.
Global Expansion Strategy
Proceeds from the Series A round will support continued development and expansion of diagnostic capabilities while driving commercial growth through direct sales and partnerships with industry leaders. The company plans to leverage both existing and new strategic partnerships to expand its global footprint.
"We're also encouraged by the strong early commercial traction and the growing interest from major strategic players looking to collaborate," Wiesner noted, highlighting the investment's strategic rationale.
aMoon, with $1.3 billion in assets under management, focuses on partnering with entrepreneurs developing groundbreaking healthcare technologies. The fund's investment in MAGENTIQ EYE aligns with its mission to support transformative health tech solutions that improve patient outcomes worldwide.
